The penetration characteristics of piperacillin-tazobactam into cortical and cancellous bone tissues were investigated in 10 patients undergoing total hip replacement. The concentration ratios of piperacillin/ tazobactam were 9.4 ± 1.8 in cancellous bone tissue and 8.0 ± 2.2 in cortical bone tissue, which were close to the 8:1 ratio of drugs administered. The mean ratios of drug concentrations in bone and plasma for cancellous and cortical tissue were 23 and 18%, respectively, for piperacillin and 26 and 22%, respectively, for tazobactam. The concentrations of tazobactam achieved are sufficient to exert anti-j-lactamase activity and supportive of clinical trials involving bone and joint infections, including those caused by P-lactamase-producing pathogens.
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One important criterion for dose selection of an antibiotic is the degree of penetration to the infected site.
Piperacillin sodium has been widely used in the treatment of serious infections, including bone and joint infections (4, 14) . Its effect, however, is limited by its susceptibility to 3-lactamase inactivation. Tazobactam (CL 298,741), a newly developed ,B-lactamase inhibitor of the penicillanic acid sulfone class, irreversibly inactivates a wide range of bacterial ,B-lactamases (2) . At the clinically relevant piperacillin/tazobactam ratio of 8:1, a concentration in the blood of 1 to 2 ,ug of tazobactam ml1-l is effective in inhibiting bacterial 3-lactamase enzymes produced by piperacillin-resistant isolates, namely, Escherichia coli, Staphylococcus sp., and Bacteroides sp. (6) . Since tazobactam rapidly and irreversibly inactivates ,-lactamases, maintenance of concentration above the MIC for most of the dosing interval at the site of infection as required for ,B-lactams may not be necessary. A combination of 3 g of piperacillin and 375 mg of tazobactam (an 8:1 ratio) given every 6 h as monotherapy has been efficacious for treating various infections, including bone and joint infections. This study was undertaken to characterize (i) the concentrations of tazobactam in bone and (ii) the ratio of piperacillin/tazobactam in cortical and cancellous bone tissues.
This Total hip replacement surgery involves resection of the femoral head and neck prior to implantation of the prosthetic hip joint. The resected femoral bone, consisting of both cortical and cancellous bones, was used in this study.
Piperacillin and tazobactam in plasma and bone tissue were analyzed by the method of Kinzig et al. (8) . For plasma, the analytical ranges were approximately 0.2 to 50 ,ug/ml for tazobactam and 0.3 to 200 ,ug/ml for piperacillin. No sample in this study was outside the validated concentration range.
For the analysis of tazobactam in bone tissue, the samples were pulverized by using liquid nitrogen. The pulverized sample (approximately 300 mg) was diluted fourfold with 0.1 M potassium dihydrogen phosphate buffer (pH 5.5). The sample was placed on a rotating shaker for 24 h at room temperature. After the 24-h extraction, the mixture was centrifuged for 10 min at 10,000 rpm, and 250 RI of the supernatant was deproteinized by the addition of 500 ,lA of acetonitrile containing the internal standard (cefpodoxime at 10 ,ug/ml). After well vortexing and centrifugation (5 min at 10,000 rpm), the acetonitrile was removed by extraction with 1 ml of dichloromethane. This mixture was centrifuged (10 min at 10,000 rpm), and 120 ,ul of the aqueous phase was injected onto the high-pressure liquid chromatography (HPLC) system, ANTIMICROB. AGENTS CHEMOTHER. Ten patients (seven male and three female) between the ages of 44 and 86 years (mean age, 63.4 years) and each weighing between 52 and 95 kg (mean, 78.2 kg) were enrolled in this study. While plasma and bone samples from 10 patients were assayed, bone data from only 9 patients were included in the overall data analysis, since the labels of the tissue samples from 1 patient were detached during shipment and we could not distinguish between bone samples of cancellous and cortical tissues.
The means ± standard deviations (SD) of concentrations of the drug in plasma after the 30-min infusion and at the time of bone removal (approximately 1 h after the initiation of infusion) were 164 ± 37.9 and 98.5 ± 19.1 ,ug/ml, respectively, for piperacillin and 15.2 ± 3.9 and 9.4 ± 2.2 ,ug/ml, respectively, for tazobactam, which were consistent with previous findings.
The concentrations of the drug in bone tissues and their ratios to the observed concentrations in plasma for piperacillin and tazobactam are summarized in Tables 1 and 2 . Patient 8 had an atypical tazobactam concentration in cancellous bone (14.7 ,ug/g), which was 3-to 11-fold higher than those for others. (This was not caused by blood contamination, and the reason for this result is unclear.) Excluding that patient, drug concentrations in bone ranged from 8.5 to 43.3 pug/g for piperacillin and 1.28 to 4.52 p,g/g for tazobactam. The means ± SD of ratios of drug concentration in bone and plasma (bone/plasma ratios) were 0.23 ± 0.12 and 0.26 ± 0.09 for piperacillin and tazobactam, respectively, in cancellous bone tissue and 0.18 ± 0.08 and 0.22 ± 0.08 for piperacillin and tazobactam, respectively, in cortical bone tissue. The concentration ratios of piperacillin/tazobactam ranged from 7.6 to 13.9 in plasma and 4.4 to 13.2 in bone tissue at the time of bone tissue removal.
Tissue penetration of piperacillin-tazobactam has been extensively studied (7) (8) (9) (10) 15) . Fat, muscle, omentum, intestinal mucosa, prostate, lung, appendix, skin, gall bladder, and gynecological tissues have been obtained from patients undergoing abdominal or thoracic surgery, cholecystectomy, hysterectomy, or resection of the prostate; and blister fluid has been obtained from healthy volunteers. Piperacillin and tazobactam 4 .52 ,ug/g for tazobactam). Our results are comparable to those for other ,-lactamase inhibitors, i.e., clavulanic acid has been reported to achieve concentrations in bone in excess of those necessary to inhibit 3-lactamases to a clinically significant extent (1, 5, 13) . The concentration ratios of piperacillin/tazobactam in cancellous bone tissue (9.4 ± 1.8) and in cortical bone tissue (8.0 ± 2.2) were similar and were also similar to the 8:1 ratio of the two drugs administered. The mean bone/plasma ratios for cancellous and cortical bone tissue were 23 and 18%, respectively, for piperacillin and 26 and 22%, respectively, for tazobactam. Since extracellular fluid constitutes about 20% of the bone tissue, our finding is consistent with results of previous experiments with 3-lactams in that both piperacillin and tazobactam do not penetrate into bone cells but are confined mainly to the extracellular fluid of bone tissues (3, 11) .
Our finding suggests that the concentrations of tazobactam achieved in bone tissues are sufficient to provide anti-plactamase activity. In addition, the maintenance of concentration ratios of piperacillin/tazobactam in both cortical and cancellous tissues is suggestive of efficacy in treatment of bone and joint infections, including those caused by ,B-lactamase producing pathogens.
